South India's Pharmaceutical Industry: The Case for South India as India's Pharmaceutical Powerhouse:
Michelle Teresa Sebastian

Issue Brief No: 4
South India's Pharmaceutical Industry:
The Case for South India as India's Pharmaceutical Powerhouse
Author: Michelle Teresa Sebastian¹

Overview

South India comprising Telangana, Andhra Pradesh, Tamil Nadu, Karnataka, Kerala, and Puducherry is not merely a significant player in India's pharmaceutical sector. By any meaningful measure of strategic value, it is the core of India's pharmaceutical sector. Together, these states account for two of the top four pharmaceutical-exporting states nationally, contributing approximately 40% of the country's bulk drug production, and host the world's foremost vaccine manufacturing cluster in Hyderabad's Genome Valley ^[1].

A comparison between South India's pharmaceutical geography and that of the major western and northern manufacturing states, reveals a fundamental divergence. South India has built a deep, strategically diversified, export-oriented pharmaceutical ecosystem grounded in industrial and scientific specialisation. Western India led by Gujarat and Maharashtra has built an industrially scaled, export-competitive manufacturing base with strong chemical integration and formulation capabilities. Northern India, anchored by Himachal Pradesh and Uttarakhand, constructed its pharmaceutical base primarily through tax-driven incentives, resulting in a cost-oriented, domestically focused volume model with limited export penetration.

This paper presents that three-way comparison in full, drawing on national production data, export statistics, cluster analysis, and regulatory records, before making the affirmative case for why South India represents India's most strategically significant pharmaceutical geography and identifying the agenda required to consolidate that position.

1. India's Pharmaceutical Geography: The National Baseline

India is one of the world's three largest pharmaceutical producers by volume, supplying approximately 20% of the world's generic medicines and nearly 60% of global vaccine demand. In FY 2024–25, India's pharmaceutical exports reached approximately US$30.47 billion, up from US$27.9 billion in FY 2023–24, with exports reaching more than 200 countries globally ^[3]. The broader industry is projected to reach USD 130 billion by 2030, driven by growing global demand for generic medicines, biosimilars, and contract manufacturing services ^[4].

Within that national story, production is strikingly concentrated. India currently has 118 pharmaceutical clusters spread across 19 states and union territories ^[5]. According to the Department of Pharmaceuticals cluster survey, the western region contains the largest concentration with 65 clusters (55%), followed by South India with 26 clusters (22%), and North and Central India with 23 clusters (19%) ^[5]. The Indian pharmaceutical cluster ecosystem supports more than 7,600 pharmaceutical enterprises and contributes approximately ₹4 lakh crore in combined domestic production and export value ^[5].

The export data presents the clearest picture of where India's pharmaceutical value is actually generated.

Table 1

State-Wise Pharmaceutical Export Values, FY 2023–24

Rank	State	Pharma Export Value (FY 2023–24)	Production Classification
1	Telangana	₹29,148.9 crore	High volume + high value
2	Gujarat	₹18,297.14 crore	High value (formulations)
3	Andhra Pradesh	₹11,390.05 crore	High volume (API)
4	Maharashtra	₹11,219.09 crore	Value + formulations

Note: Data sourced from Pharmexcil (2024b) and Department of Pharmaceuticals, Government of India (n.d.-a). Export values are in Indian Rupees crore. Production classification follows Department of Pharmaceuticals typology.

Two of the top four pharmaceutical-exporting states in India are in South India. Telangana leads the country by a substantial margin ₹29,148.9 crore in exports, exceeding second-ranked Gujarat by nearly ₹11,000 crore, a gap larger than the entire pharmaceutical export value of Maharashtra. Andhra Pradesh sits at third with ₹11,390.05 crore, separated from fourth-ranked Maharashtra by less than ₹200 crore. The geographic concentration of export value in South India is not coincidental; it reflects decades of strategic specialisation in high-demand pharmaceutical segments. Gujarat and Maharashtra together account for ₹29,516.23 crore in pharmaceutical exports, confirming that Western India is a formidable industrial presence that must be included in any serious regional analysis.

India currently stands only 11th in the global pharmaceutical export market in terms of value. However, with an increasing focus on quality and compliance, and with South India spearheading this transformational shift, the Indian pharmaceutical industry is expected to follow a trajectory similar to that of the IT services sector evolving from a reliable global service provider into a global powerhouse. This transformation is being driven by a strong and continuously evolving quality framework, the availability of highly skilled personnel, and the presence of reputed educational and research institutions aligned with the needs of the global healthcare community. The differentiation and competitive advantages are outlined later in this document ^[4].

2. A Three-Region Production Comparison: South, West, and North India

To evaluate South India's strategic position, it is necessary to examine what each major pharmaceutical region produces, how that production base was built, and what the trajectory implies for future competitiveness. The differences between regions are structural and strategic rather than merely a matter of scale.

2.1 The Northern Model: Tax-Driven Volume Manufacturing

The northern pharmaceutical manufacturing states built their industry through a fundamentally different mechanism than South or West India. Himachal Pradesh and Uttarakhand became major pharmaceutical producers following the central government's Special Category Area industrial incentives in the early 2000s, which offered excise duty exemptions, income tax holidays, and capital investment subsidies to manufacturers relocating or establishing plants in these hill states.

The results were impressive in volume terms. Himachal Pradesh's Baddi industrial corridor became one of India's largest single pharmaceutical manufacturing zones, home to more than 555 licensed pharmaceutical units. Uttarakhand's Haridwar and Dehradun clusters added hundreds more. Together, these two states account for a substantial share of India's domestic tablet and capsule output. The model has a structural ceiling, however: the tax incentives that drove location decisions began phasing out from 2010, and manufacturers in these clusters face the challenge of sustaining competitiveness once the original cost subsidy disappears.

The northern states' pharmaceutical profile is characterised by mass-scale generic tablet and capsule manufacturing, a primary orientation toward the domestic Indian market rather than regulated export markets, minimal API production capacity, no significant biologics or vaccine manufacturing, and limited R&D infrastructure connected to commercial pharmaceutical development. Uttar Pradesh, with 408 licensed units, follows a similar pattern: large unit count, domestic orientation, and no significant presence in the national pharmaceutical export rankings.

2.2 The Western Model: Industrial Scale and Export Integration

Western India principally Gujarat and Maharashtra represent India's largest pharmaceutical manufacturing region by cluster density and licensed unit count. Gujarat alone holds 3,332 licensed pharmaceutical manufacturing units, more than six times the count of any single South Indian state. Maharashtra adds a further 929. Together, they rank second and fourth respectively in national pharmaceutical export value.

Gujarat's pharmaceutical strength derives from its deeply integrated chemical ecosystem. The state is home to major bulk chemical and API producers, and its formulation manufacturing infrastructure is extensive. The Ahmedabad–Vadodara pharmaceutical corridor and Surat's chemical complex provide the raw material and intermediate supply chains that underpin large-scale generic formulation production. Maharashtra's strength is complementary: the Mumbai-Pune corridor hosts major multinational pharmaceutical operations, a growing CDMO sector, and India's most significant vaccine manufacturer by volume the Serum Institute of India, headquartered in Pune.

Western India is both an export competitor and a volume leader. Its pharmaceutical base, while large, is concentrated in the formulation and packaging segment, with relatively lower intensity in the high-value biologics, biosimilar, and original research segments that will define the next generation of pharmaceutical competitiveness.

2.3 The South Indian Model: Strategic Specialisation and Export Orientation

South India's pharmaceutical geography developed through a different logic. Rather than responding to tax incentives or leveraging chemical industrial scale, South Indian pharmaceutical clusters grew from industrial and scientific specialisation: Hyderabad's bulk chemical industry providing natural feedstocks for API manufacturing; Bengaluru's scientific talent pool feeding biotechnology and biosimilar development; Chennai's engineering and manufacturing infrastructure supporting formulations and medical devices; and Visakhapatnam's emerging role as a dedicated pharmaceutical production hub.

The consequence is a manufacturing base that is qualitatively different from the north and strategically differentiated from the west. South India produces at the upper end of the pharmaceutical value chain: APIs that northern states cannot make, vaccines that no other region of India can supply at equivalent scale, biosimilars that compete globally, and formulations destined for the world's most stringent regulated markets.

2.4 Head-to-Head: All Three Regions on Key Pharmaceutical Indicators

Table 2 presents a direct comparison across the dimensions that define pharmaceutical sector quality and strategic positioning across all three regions.

Table 2

South India, West India, and North India: Pharmaceutical Sector Comparison by State

Indicator	Telangana	Andhra Pradesh	Tamil Nadu	Karnataka	West Indian States (GJ, MH)	North Indian States
Primary production type	Bulk drugs, APIs, vaccines	APIs, formulations	Formulations, medical devices	Biotech, biosimilars	Large-scale formulations, APIs, bulk chemicals (GJ); formulations & CDMO (MH)	Generic tablets, capsules
Export value (FY 2023–24)	₹29,148.9 Cr (Rank 1)	₹11,390.05 Cr (Rank 3)	Rapidly growing	Strong R&D base	GJ: ₹18,297.14 Cr (Rank 2); MH: ₹11,219.09 Cr (Rank 4)	Primarily domestic market
Licensed pharma units	523	261	514	376	GJ: 3,332 / MH: 929	HP: 555 / UP: 408 / UK: limited
Pharma clusters	Major Hyderabad cluster (HPC)	8 clusters; JN Pharma City	Growing Chennai corridor	Bengaluru biotech SEZ	GJ: 12 clusters (Ahmedabad, Vadodara); MH: Pune–Mumbai corridor	HP: 7 / RJ: 7 clusters
Share of bulk drug production	~35–40% of national output	Major API producer	Growing	Biotech-focused	Moderate; strong chemical feedstock base (GJ)	Negligible API base
Vaccine / biologics capacity	World leading (Genome Valley)	Limited	Limited	Significant (Biocon)	Moderate; Serum Institute (MH); limited GJ biologics	None
R&D and innovation base	NIPER Hyd; Dr. Reddy's; Aurobindo	NIPER Visakhapatnam	IIT Madras; Pfizer R&D	IISc; NCBS; Syngene CDMO	NIPER Ahmedabad; ICT Mumbai; Cipla & Sun Pharma R&D (MH)	Minimal tax-driven model
Growth model	Strategic investment (HPC: USD 9.7 B)	Central bulk drug park (USD 125 M)	Policy-driven (Life Sciences Policy 2022)	Subsidy-led innovation (25% biosimilar grant)	Industrial scale + export manufacturing; strong PLI beneficiary	Tax incentive-driven (phasing out)
MNC manufacturing presence	Yes (multiple)	Yes (Pfizer, Mylan, Lupin)	Yes (Pfizer)	Yes (multiple MNCs)	Yes (multiple MNCs in GJ and MH)	Limited

Note: Data sourced from Department of Pharmaceuticals, Government of India (n.d.-a, n.d.-b), Pharmexcil (2024b), Ministry of Statistics and Programme Implementation (n.d.-b), Invest Telangana (2023), and state government investment promotion agencies. GJ (Gujarat); MH (Maharashtra); HP (Himachal Pradesh); UP (Uttar Pradesh); UK (Uttarakhand); RJ (Rajasthan). West Indian States column reflects the aggregate profile of Gujarat and Maharashtra. North Indian States column reflects the aggregate profile of HP, UP, UK, and RJ.

The contrast that emerges from this three-way comparison is one of strategic direction. Northern states produce more of what India already makes in abundance: undifferentiated generic tablets and capsules for a price-sensitive domestic market. Western states produce at industrial scale with strong export credentials but limited depth in high-value biologics and research-intensive segments. South Indian states produce what India needs more of to remain globally competitive: APIs, vaccines, biosimilars, and research-intensive specialty formulations.

2.5 The Pharmaceutical Units Picture

National data on licensed pharmaceutical manufacturing units reveals where India's manufacturing capacity is physically located and, critically, what that capacity actually produces.

Table 3

Number of Licensed Pharmaceutical Manufacturing Units by State

State	Licensed Pharma Units	Region
Gujarat	3,332	West India
Maharashtra	929	West India
Himachal Pradesh	555	North India
Telangana	523	South India
Tamil Nadu	514	South India
Uttar Pradesh	408	North India
Karnataka	376	South India
Andhra Pradesh	261	South India

Note: Data sourced from Ministry of Statistics and Programme Implementation (n.d.-b) and Department of Pharmaceuticals, Government of India (n.d.-a). South India states are Telangana, Tamil Nadu, Karnataka, and Andhra Pradesh. North India states relevant to pharmaceutical manufacturing include Himachal Pradesh and Uttar Pradesh.

South India's four core states - Telangana (523), Tamil Nadu (514), Karnataka (376), and Andhra Pradesh (261) collectively hold 1,674 licensed pharmaceutical manufacturing units. Gujarat's 3,332 units and Himachal Pradesh's 555 units reflect high counts of small and medium-scale formulation and packaging units, many established primarily for tax benefits and serving domestic consumption. Maharashtra's 929 units include a meaningful proportion of export-oriented and multinational operations. South India's units are concentrated in larger-scale, export-oriented API and biologics manufacturing operations. Export value per manufacturing unit the most meaningful productivity metric strongly favours South India.

2.6 Regional Cluster Overview

India's 118 pharmaceutical clusters are distributed unevenly across its three major pharmaceutical regions, reflecting distinct historical strategies and industrial logics.

Table 4

Regional Pharmaceutical Cluster Overview: South, West, and North India

Indicator	South India	West India	North India
Major States	Telangana, Andhra Pradesh, Karnataka, Tamil Nadu	Maharashtra, Gujarat, Goa	Himachal Pradesh, Uttar Pradesh, Uttarakhand, Rajasthan
Primary Strengths	APIs, vaccines, biotech, biosimilars, R&D	Large-scale manufacturing, exports, formulations	Generic tablets and capsule manufacturing
Cluster Share	26 clusters (22%)	65 clusters (55%)	23 clusters (19%)
Export Orientation	Strong global exports	Large export manufacturing scale	Primarily domestic market
Innovation Capacity	High	Moderate to high	Limited
API Ecosystem	Very strong	Strong	Limited
Vaccine / Biologics	Global leadership	Moderate	Minimal
Growth Model	Strategic specialisation	Industrial and export scale	Tax incentive-driven

Note. Cluster data sourced from Department of Pharmaceuticals, Government of India (n.d.-b), Pharmaceutical Cluster Survey. South India includes Telangana, Andhra Pradesh, Karnataka, and Tamil Nadu. West India includes Maharashtra, Gujarat, and Goa. North India includes Himachal Pradesh, Uttar Pradesh, Uttarakhand, and Rajasthan.

Western India's cluster dominance by (65 clusters, 55%) reflects decades of industrial accumulation rather than strategic pharmaceutical targeting. South India's 26 clusters (22%), though fewer in number, are disproportionately concentrated in high-value segments: API manufacturing, biologics, and research-linked production. North India's 23 clusters (19%) are almost entirely in the formulation and packaging segment, with no meaningful cluster presence in the API or biologics categories.

3. Why South India Leads: The Affirmative Case

Having established what each region produces and how those production bases compare, this section makes the affirmative argument: South India is not just India's current pharmaceutical export leader it is the geography best positioned to lead India's pharmaceutical future, for reasons that are structural, strategic, and increasingly backed by policy and investment.

3.1 South India Holds the Positions That Matter Most

The most direct evidence for South India's strategic pre-eminence is the export data. Telangana's ₹29,148.9 crore in pharmaceutical exports makes it India's leading pharmaceutical-exporting state by a margin of ₹10,851.76 crore over Gujarat a gap larger than the entire pharmaceutical export value of Maharashtra. Andhra Pradesh at third place with ₹11,390.05 crore demonstrates that South India's leadership is not dependent on a single state. Together, Telangana and Andhra Pradesh account for approximately ₹40,538.95 crore in pharmaceutical exports more than the combined total of Gujarat and Maharashtra.

Neither northern state with a significant pharmaceutical manufacturing base Himachal Pradesh nor Uttarakhand appears in the national top four export rankings. This is the most fundamental summary of the structural divergence: northern states produce large volumes of pharmaceuticals; South Indian states export them into the world's most demanding markets.

3.2 South India Controls the Critical Inputs: APIs and Bulk Drugs

Telangana alone contributes approximately 35–40% of India's total bulk drug production. Hyderabad is recognised as India's Bulk Drug Capital. Andhra Pradesh is one of India's largest API producers. Combined, these two states give South India effective control over the critical upstream input that determines the cost and availability of most generic medicines manufactured anywhere in India.

This upstream control is strategically significant in a way that northern generic tablet manufacturing and even western formulation production are not. Companies that make APIs and bulk drugs set the cost floor for the entire pharmaceutical value chain. As India pursues API self-reliance in the context of China+1 geopolitical diversification, the states that already have the manufacturing infrastructure Telangana and Andhra Pradesh will be the primary beneficiaries of both government investment and private capital redirection.

3.3 South India Supplies the World's Vaccines: An Irreplaceable Position

India supplies nearly 60% of global vaccine demand by volume, and the overwhelming majority of that production originates in Hyderabad's Genome Valley. Bharat Biotech developer of Covaxin and the world's first rotavirus vaccine approved for global use along with Biological E, Shantha Biotech, and Indian Immunologicals collectively make Hyderabad the single most important vaccine manufacturing cluster on earth. No northern state has any equivalent position in vaccines or biologics. Western India's Serum Institute of India, headquartered in Pune, is the world's largest vaccine manufacturer by total volume an important qualification but Hyderabad's cluster remains unmatched in scientific breadth and strategic depth.

Vaccines are not low-margin commodities. They represent high-value, technically sophisticated biological manufacturing that requires specialised infrastructure, cold-chain logistics, and quality systems that have taken decades to build. This is precisely the type of pharmaceutical production that India needs to maintain and expand as it seeks to transition from volume-based to value-based pharmaceutical exports.

3.4 Karnataka Provides the Biosimilar and R&D Platform

If Telangana represents South India's volume and export strength, Karnataka represents its future. Biocon Biologics, headquartered in Bengaluru, is ranked among the top five global biosimilar companies by market share, with commercial operations across more than 100 countries ^[8]. The broader Karnataka biotechnology industry was valued at USD 92 billion in 2023 ^[9]. Syngene International a Biocon subsidiary and a leading contract research and manufacturing organisation serves eight of the top ten global pharmaceutical companies. That is not a supplier relationship; it is a deep technical partnership of the kind that defines the highest-value end of the pharmaceutical services market.

Karnataka's 25% biosimilar production subsidy, introduced in FY 2024–25, attracted ₹2,400 crore in new investment within a single year demonstrating that state-level policy can move capital into high-value pharmaceutical manufacturing rapidly when the underlying industrial ecosystem is ready to absorb it. No northern state has a comparable CDMO platform, and none is building one at equivalent scale.

3.5 Tamil Nadu: Manufacturing Sophistication and Emerging CDMO Capacity

Tamil Nadu completes South India's pharmaceutical picture. With 514 licensed manufacturing units nearly equal to Telangana and a growing presence in medical devices, specialty formulations, and CDMO services, Tamil Nadu adds manufacturing depth and diversification to South India's pharmaceutical profile.

The Tamil Nadu Life Sciences Promotion Policy 2022 designated pharmaceuticals and biotechnology as a Sunrise Sector, reducing drug licence approval time from 90 to 30 days and introducing a comprehensive incentive framework. The IIT Madras Research Park CDMO model where pharmaceutical companies co-locate with one of India's premier research institutions is a replicable template for the research-to-commercial pipeline that the industry needs. Pfizer's dual R&D and manufacturing presence in Chennai is the most visible signal of international confidence in Tamil Nadu as both a research and production location.

3.6 The Growth Model Is Sustainable; the Northern Model May Not Be

A fundamental difference between South India's pharmaceutical growth model and that of the northern manufacturing states is durability. South India's pharmaceutical clusters grew from industrial logic: the availability of chemical feedstocks, scientific talent, port infrastructure, and accumulated technical expertise. That logic does not expire.

The northern pharmaceutical manufacturing hubs were substantially built on time-limited tax incentives. As those incentives have phased out or reduced in value, the structural vulnerability of the model has become apparent. Manufacturers in Baddi and Haridwar do not have the API capabilities, the regulatory relationships, or the technical infrastructure to pivot easily toward export-oriented or high-value production. They face a strategic challenge that South India, with its deeper foundations, does not face in the same form.

South India's investments, Hyderabad Pharma City (USD 9.7 billion planned investment, 19,000 acres), the East Godavari bulk drug park (USD 125 million in central government funding), and Karnataka's biosimilar ecosystem are strategic infrastructure investments with multi-decade returns. Western India similarly benefits from durable industrial infrastructure, but its growth is more dependent on maintaining chemical-cost advantages that are increasingly contested by Southeast Asian competitors.

4. Strategic Fit Assessment: A Three-Region Summary

Table 5 synthesises the three-way comparison into a concise strategic assessment across the dimensions most relevant to India's pharmaceutical future.

Table 5

South India, West India, and North India: Strategic Pharmaceutical Fit Assessment

Strategic Dimension	South India	West India	North India	Advantage
Export competitiveness	Ranks 1st and 3rd nationally	Ranks 2nd and 4th nationally	Not in top 4	South India
API / bulk drug leadership	~40% of national output	Strong chemical feedstock base	Negligible	South India
Vaccine & biologics	~60% of global supply (Hyderabad)	Moderate (Serum Institute, MH)	None	South India
Biosimilars	Top 5 globally (Biocon, Karnataka)	Emerging	None	South India
CDMO potential	Syngene (Bengaluru); IIT Madras (Chennai)	Growing (MH pharmaceutical parks)	Minimal	South India
Research infrastructure	IISc, IIT Madras, IIT Hyd, NIPER Hyd	NIPER Ahmedabad; ICT Mumbai	Limited pharma-linked R&D	South India
Growth model durability	Strategic investment + policy	Industrial scale + PLI beneficiary	Tax incentives (phasing out)	South India
MNC confidence	Pfizer (Chennai & Vizag); multiple MNCs	Multiple MNCs in GJ and MH	Minimal MNC presence	South India
AI & technology readiness	High Bengaluru & Hyderabad tech hubs	Moderate Mumbai tech ecosystem	Low	South India

Note: Assessment based on data from Department of Pharmaceuticals, Government of India (n.d.-a), Pharmexcil (2024b), Invest Telangana (2023), Biocon Biologics (2025), Guidance Tamil Nadu (2022), and Ministry of Statistics and Programme Implementation (n.d.-a). CDMO (Contract Development and Manufacturing Organisation). MNC (Multinational Corporation). GJ (Gujarat); MH (Maharashtra).

South India has developed a significant advantage in pharmaceutical manufacturing through decades of experience in successfully meeting stringent international regulatory requirements, including those of the US FDA, EMA, and other global agencies. The region has undergone the rigorous learning curve associated with global compliance standards and has built strong capabilities in quality systems, regulatory practices, advanced manufacturing technologies, and documentation processes. This progress has been further strengthened by the presence of several multinational pharmaceutical companies and globally oriented Indian firms, which have contributed to the transfer of technical expertise and best practices. As a result, South India today possesses a large pool of qualified, trained, and industry-experienced professionals who can support and accelerate the growth of newer manufacturing units, thereby strengthening and scaling up the regions already established pharmaceutical export base.

South India holds the advantage on every dimension that determines long-term pharmaceutical competitiveness. Western India holds a credible position on export scale, MNC presence, and industrial infrastructure, and represents South India's most meaningful strategic peer rather than a direct competitor the two regions are more complementary than substitutable in the national pharmaceutical ecosystem. Northern states hold the advantage in one area only: raw unit count of licensed manufacturers. But manufacturing unit count is the least meaningful measure of pharmaceutical sector quality. What matters is what those units produce, where it goes, and what it is worth and on all three measures, South India leads by a significant margin.

5. Structural Challenges South India Must Address

Acknowledging South India's pharmaceutical pre-eminence does not mean ignoring the structural challenges that have constrained the region's ability to capture full economic value from its manufacturing base. Three challenges are particularly important.

5.1 The Volume–Value Gap

Despite leading India in bulk drug production and pharmaceutical exports, South India particularly Telangana and Andhra Pradesh remains predominantly API- and generic-oriented. India holds only approximately 3% of global pharmaceutical exports by value despite supplying 20% of global generic volume ^[4]. Closing this gap requires accelerating South India's transition toward biosimilars, CDMOs, specialty formulations, and original drug development all areas where South India has the base infrastructure but needs significantly deeper investment.

5.2 R&D Investment Below Global Benchmarks

Indian pharmaceutical companies spend 5–7% of revenues on R&D on average, compared to 15–20% for major multinational pharmaceutical companies ^[12]. National pharmaceutical R&D investment has grown from USD 0.5 billion in 2010 to USD 2.5 billion in 2023, projected to reach USD 5.2 billion by 2030 ^[12], but remains modest relative to global comparators. South India has the institutional infrastructure IISc, NCBS, IIT Madras, IIT Hyderabad, and NIPER Hyderabad to support significantly deeper pharmaceutical R&D. The connection between these institutions and commercial drug development pipelines needs systematic strengthening through structured industry-academia partnerships and dedicated technology transfer offices.

5.3 Regulatory Friction and Compliance Costs

The US FDA conducted over 256 inspections of Indian pharmaceutical facilities in 2024 — the largest concentration of inspections outside the United States ^[13]. India's compliance record is broadly strong, but warning letters and import alerts have outsized reputational and commercial effects. Tamil Nadu's reduction of domestic drug licence approval time from 90 to 30 days demonstrates what is achievable at the state level. Equivalent improvements at the national CDSCO level would lower barriers for smaller South Indian exporters attempting to enter regulated markets.

5.4 Environmental and Sustainability Challenges

South India’s pharmaceutical clusters, and Hyderabad’s in particular, have long faced criticism for severe water and soil pollution arising from bulk drug manufacturing. A 2018 investigation by Nordea and the Changing Markets Foundation documented that pharmaceutical companies in Hyderabad were continuing to discharge untreated or inadequately treated wastewater into surrounding water bodies and soil, with concentrations of heavy metals such as hexavalent chromium, arsenic, nickel, and copper detected at levels orders of magnitude above WHO and US EPA maximum contaminant limits ^[19]. Industrial solvents including benzene, toluene, chloroform, methylene chloride, and vinyl chloride were found in samples adjacent to major pharmaceutical manufacturing sites across the Patancheru-Bollaram, Gaddapotharam, Bachupally, and Pashamylaram industrial zones.

The environmental cost extends beyond water. Studies have shown severe soil quality degradation in areas surrounding pharmaceutical industries in Medchal, Bachupally, and Dundigal, with the majority of samples falling into the “poor” category of the Soil Quality Index ^[19]. Air pollution from pharmaceutical production has been associated with a documented rise in respiratory ailments in communities adjacent to manufacturing zones. Of particular concern is the link between uncontrolled antibiotic manufacturing discharge and the spread of antimicrobial resistance (AMR): academic research has found antibiotic concentrations in the Hyderabad area and the Musi River at levels 1,000 times higher than those found in rivers in developed countries, contributing to the proliferation of multi-drug-resistant bacteria ^[19]. The AMR risk does not respect national borders: a 2010 study found that seven out of eight travellers returning from India to Sweden carried drug-resistant bacteria in their gut, underlining the global public health dimension of localised pharmaceutical pollution.

Addressing environmental performance is not merely a social obligation but a strategic commercial imperative. European and US procurement bodies have increasingly introduced environmental criteria into pharmaceutical supply contracts. Sweden introduced environmental standards into national pharmaceutical procurement contracts as early as 2012, and European NGOs have called for major procurement bodies including the UK’s National Health Service to blacklist the worst offending polluters ^[19]. South India’s pharmaceutical manufacturers who aspire to grow their presence in regulated export markets must treat environmental compliance not as a cost to be minimised but as a prerequisite for continued market access. Investing in zero-liquid-discharge systems, common effluent treatment infrastructure, and independently verified environmental monitoring would simultaneously protect local communities and insulate South Indian manufacturers from growing regulatory and reputational risk in their key export markets.

5.5 Leveraging India’s Free Trade Agreements for Pharmaceutical Growth

India has concluded or is actively negotiating more than six Free Trade Agreements (FTAs) with major pharmaceutical export destinations, creating a significant and as yet incompletely utilised opportunity for South India’s pharmaceutical sector. The India–UK Comprehensive Economic Partnership Agreement (CEPA), signed in July 2025, eliminates tariffs on a broad range of pharmaceutical products and includes provisions for Mutual Recognition of Good Manufacturing Practice (GMP) inspections, which would reduce the duplicative compliance burden that Indian exporters currently bear in accessing the UK market ^[20]. Ongoing negotiations toward an India–EU Broad-based Trade and Investment Agreement, targeting a combined market of USD 572.3 billion, similarly include pharmaceutical chapters covering tariff reduction, regulatory harmonisation, and intellectual property frameworks relevant to generic and biosimilar market entry ^[20].

Beyond tariff elimination, the FTA architecture creates several specific pharmaceutical cooperation mechanisms that South India is well-positioned to exploit. Mutual Recognition Agreements (MRAs) on pharmaceutical inspections reduce duplicative regulatory audits and lower the cost of maintaining market access across multiple jurisdictions simultaneously, a particular advantage for South India’s export-oriented API and formulation manufacturers who serve the US, EU, and UK markets in parallel. Intellectual property chapters in modern FTAs include provisions on data exclusivity and patent linkage that affect generic and biosimilar market entry timelines; South Indian manufacturers need to engage proactively with these provisions to protect their competitive position in regulated markets. Additionally, FTAs with Gulf Cooperation Council (GCC) states and ASEAN members open emerging markets where South India’s vaccine and API exports can grow with reduced tariff friction. The full realisation of these FTA benefits requires South India’s pharmaceutical industry to invest in the regulatory harmonisation capacity to operate simultaneously across multiple international standards frameworks.

5.6 Data Integrity in Pharmaceutical Manufacturing

Data integrity failures represent one of the most persistent and commercially consequential compliance risks facing India’s pharmaceutical industry, and South India is not immune. Data integrity refers to the completeness, consistency, and accuracy of data generated throughout the pharmaceutical manufacturing lifecycle, from raw material testing and in-process quality controls through to batch release and post-market surveillance. The US FDA and the European Medicines Agency have consistently identified data integrity deficiencies as the primary driver of warning letters, import alerts, and manufacturing site shutdowns in India ^[21]. Of the 42 warning letters issued by the US FDA’s Office of Manufacturing Quality in 2016, a significant proportion cited data integrity violations including falsification of records, backdating of test results, and manipulation of chromatographic data.

The commercial consequences of data integrity failures are severe and disproportionate relative to their root causes. A single warning letter or import alert can result in the suspension of a manufacturing site from supplying regulated markets, triggering supply disruptions and contract losses that may take years to remediate. The Economic Times estimated that US FDA regulatory actions wiped out nearly ₹15 billion in market capitalisation from India’s top five pharmaceutical companies in a single year ^[21]. For South India’s export-dependent manufacturers, the reputational damage of a data integrity finding extends beyond the individual site to the broader perception of Indian pharmaceutical quality in the eyes of foreign regulators and procurers.

Addressing data integrity systematically requires investment in electronic quality management systems (eQMS), computerised laboratory systems compliant with 21 CFR Part 11 requirements, audit trail review protocols, and cultural transformation programmes that treat data accuracy as a non-negotiable manufacturing value rather than an administrative overhead. South India’s pharmaceutical industry, given its proximity to Bengaluru and Hyderabad’s technology ecosystems, is better placed than any other Indian pharmaceutical region to integrate digital quality infrastructure at scale. Building data integrity capabilities proactively, rather than reactively in response to regulatory findings, would not only reduce compliance risk but would accelerate the transition to advanced manufacturing practices that global pharmaceutical partners increasingly require as a condition of partnership.

6. The Policy and Investment Tailwinds

The case for South India is reinforced by a favourable national policy environment that specifically supports the region's strategic priorities.

PLI Scheme for Pharmaceuticals. The ₹15,000 crore production-linked incentive scheme has supported 55 projects, with an API sub-scheme worth ₹6,940 crore. By May 2024, PLI investments totalled ₹29,268 crore, commissioning 261 manufacturing plants and creating over 71,000 jobs ^[14]. South India's API base positions it as the scheme's primary geographic beneficiary.

PRIP Scheme. Launched in August 2023 with ₹5,000 crore in total allocation, including ₹700 crore earmarked for seven Centres of Excellence at NIPER institutes ^[15], NIPER Hyderabad is positioned for significant allocation. This scheme directly supports South India's research infrastructure advantage.

China+1 API Diversification. As of March 2025, India had brought 38 previously China-dependent critical APIs into domestic production ^[16]. South India's bulk drug parks particularly in Andhra Pradesh and Telangana are the primary geographic beneficiaries. Aurobindo Pharma's new penicillin G manufacturing facility is projected to reduce Indian dependence on Chinese API supply by 28%.

Trade Agreement Access. The India–UK Comprehensive Economic and Trade Agreement, signed in July 2025, and ongoing India–EU free trade agreement negotiations targeting a USD 572.3 billion market open high-value export corridors for South India's regulated-market-oriented manufacturers. South India's existing MNC presence positions it as the primary beneficiary of these new trade channels.

Vision Pharma 2047. Gazetted in August 2023, this strategic framework targets India's transition from volume-based to value-based pharmaceutical production a transition that South India is already making, and that aligns directly with the region's existing industrial strengths.

7. The Technology Frontier: AI-Enabled Pharmaceutical Innovation

Artificial intelligence is poised to reshape pharmaceutical manufacturing, drug discovery, regulatory compliance, and healthcare delivery at a pace that will reward geographies already embedded in technology ecosystems. Key areas of impact include AI-driven molecule prediction and drug discovery, clinical trial optimisation, predictive quality control, manufacturing automation, supply-chain forecasting, regulatory documentation support, pharmacovigilance, and personalised medicine.

South India's technology ecosystem particularly the Bengaluru and Hyderabad technology hubs positions the region strongly for AI-enabled pharmaceutical innovation. Bengaluru hosts the highest concentration of data science and artificial intelligence talent in India, directly adjacent to Karnataka's biosimilar and CDMO sector. Hyderabad's pharmaceutical cluster and its proximity to a major technology services ecosystem create natural synergies for AI-integrated drug development and manufacturing operations. This technology–pharmaceutical adjacency is not replicated at comparable depth in northern pharmaceutical clusters and is present but less deeply integrated in western India.

Global pharmaceutical companies are actively seeking manufacturing and development partners in geographies that offer both pharmaceutical expertise and technology infrastructure. South India uniquely offers both.

8. What Needs to Happen: A South India Agenda

South India's pharmaceutical leadership is real but not guaranteed. Translating current strengths into durable, growing advantage requires deliberate action across five strategic priorities.

8.1 Accelerate the CDMO and Biosimilar Transition

The global CDMO market is projected to reach USD 44.6 billion by 2029 ^[17]. South India should deliberately position itself as India's primary CDMO geography, replicating and scaling the Syngene and IIT Madras models across Bengaluru, Chennai, and Hyderabad. Karnataka's 25% biosimilar production subsidy model should be evaluated for extension to Telangana and Tamil Nadu to create a coherent South Indian biosimilar corridor with the scale to attract global partners.

8.2 Deepen the API Self-Reliance Agenda

South India's bulk drug parks particularly Andhra Pradesh's East Godavari park and Telangana's Hyderabad Pharma City are critical infrastructure for India's API self-reliance objectives. Coordinated completion and full buildout of these facilities, with streamlined environmental and regulatory clearances, would create an API manufacturing base that no other region in Asia outside China can match.

8.3 Invest in Research-to-Commercial Pipelines

South India's research institutions represent a scientific asset not yet fully connected to commercial drug development. Structured industry-academia partnership frameworks, co-funded doctoral programmes, and technology transfer offices at every major research institution would systematically close the gap between South India's scientific depth and its commercial pharmaceutical output. The IIT Madras Research Park model provides a scalable template.

8.4 Build a South India Pharmaceutical Brand

South India as a region lacks a coordinated identity in global pharmaceutical conversations. A South India Life Sciences Council presenting a unified voice to global investors, regulators, and trading partners, and coordinating policy advocacy across the constituent states would accelerate the region's recognition as a coherent pharmaceutical geography and improve its competitive position relative to established hubs in Ireland, Singapore, and the United States.

8.5 Strengthen the Regulatory Ecosystem

South India's pharmaceutical industry operates under approvals coordinated through the Central Drugs Standard Control Organisation and State Drug Control Departments. Telangana and Andhra Pradesh focus heavily on API approvals, environmental clearances, and export-oriented compliance systems. Karnataka and Tamil Nadu increasingly support biotech, biosimilar, and medical device regulatory ecosystems. Harmonising and accelerating approval timelines across these state systems and advocating for equivalent improvements at the CDSCO level would reduce the compliance cost burden that disproportionately affects smaller exporters.

9. Conclusion

The data supports a clear conclusion. South India holds the leading pharmaceutical export position in India through Telangana and third position through Andhra Pradesh. It contributes approximately 40% of India's bulk drug production, supplies the overwhelming majority of the world's vaccine demand through Hyderabad's Genome Valley, and is home to India's most globally significant biosimilar company through Karnataka. Its 1,674 licensed manufacturing units across four states produce pharmaceuticals that reach more than 200 countries ^[18].

The three-region comparison presented in this paper shows that each region occupies a distinct strategic position. Northern pharmaceutical manufacturing states despite high unit counts operate in fundamentally less strategically positioned segments of the pharmaceutical value chain, producing generic tablets primarily for domestic consumption. Western India occupies a credible middle ground: industrially scaled, export-competitive, and home to the world's largest vaccine producer by volume, but with limited depth in the high-value biosimilar, CDMO, and research-intensive segments that will define the next decade of pharmaceutical competition. South India produces APIs, vaccines, biosimilars, and specialty formulations for the world's most demanding markets and has the research infrastructure and policy environment to deepen that advantage.

The volume–value gap remains South India's most important strategic challenge. But it is a challenge that South India precisely because of its existing strengths in API production, biologics, and research infrastructure is best positioned to address. The northern manufacturing states cannot make the same transition: they lack the API base, the biologics infrastructure, the research ecosystem, and the export market relationships that would enable it. Western India can make parts of the transition, but its starting point is different and its scientific infrastructure shallower.

South India's pharmaceutical future depends on the choices made in the next three to five years: how quickly it accelerates its CDMO and biosimilar platforms, how effectively it connects research institutions to commercial drug development, how strategically it positions itself to capture the global tailwinds of China+1 API diversification and biosimilar patent cliffs, and how coherently it presents itself to global investors as a unified pharmaceutical geography. The infrastructure and the talent are present. The direction is clear.

Acknowledgements

The preparation of this paper was supported through industry interactions, secondary research, policy documents, and expert insights from professionals associated with India's pharmaceutical and healthcare ecosystem. Special acknowledgements to:

• Mentor - T. S. Tirumurti, Deccan Centre for International Relations

• Peer review - Balasubramanian Chandrashekar, Deccan Centre for International Relations

• Professionals associated with Dr. Reddy's Laboratories

• Representatives connected with Dadha Pharmaceuticals

• Shaji Vikraman - Rtd. Resident Editor, Indian Express

• Arundati Mech - Rtd. Regional Director, Reserve Bank of India

• Additional stakeholders from pharmaceutical manufacturing, biotechnology, healthcare, export logistics, and industrial development ecosystems

References

1Author: Michelle Teresa Sebastian, 2nd Year BA (Economics and Psychology), Christ University, Bangalore.

Aurobindo Pharma. (2024). Annual report 2023–24. Aurobindo Pharma Limited.

[10] Biocon Biologics. (2025). Corporate website.

BioSpectrum India. (2024). Biopharma industry reports 2024.

Brickwork Ratings. (2024). Drugs and pharmaceuticals industry report 2024.

Central Drugs Standard Control Organisation. (n.d.). Regulatory framework documentation. Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India.

Chandra Shekhar, S. (2024). Indian pharmaceutical industry: Past, present, and future outlook 2024–2030. Mahat Research and Advisory / IGNOU.

[1, 11, 18] Department of Pharmaceuticals, Government of India. (n.d.-a). Official portal.

[5] Department of Pharmaceuticals, Government of India. (n.d.-b). Pharmaceutical cluster survey report.

Department of Pharmaceuticals, Government of India. (2024). Industry data compiled from pharmaceutical export and cluster studies. Government of India.

Drug Patent Watch. (2025). Balancing opportunity and risk in India's pharmaceutical sector.

[10] Guidance Tamil Nadu. (2022). Life sciences promotion policy 2022. Tamil Nadu Industrial Development Corporation.

Hyderabad Pharma City. (n.d.). Official website.

India Brand Equity Foundation. (n.d.-a). Himachal Pradesh state presentation. Ministry of Commerce and Industry.

India Brand Equity Foundation. (n.d.-b). Pharmaceutical industry in India. Ministry of Commerce and Industry.

Invest India. (2025). Pharmaceutical sector spotlight: Driving innovation in India.

[6, 11] Invest Telangana. (2023). Pharma sector. Telangana State Industrial Infrastructure Corporation.

[7] ISPE. (2025, March–April). Indian pharmaceutical industry: Creating global impact. Pharmaceutical Engineering.

Ministry of Chemicals & Fertilizers, Government of India. (n.d.). Annual report. Ministry of Chemicals & Fertilizers.

Ministry of Statistics and Programme Implementation, Government of India. (n.d.-a). Annual survey of industries. Government of India.

Ministry of Statistics and Programme Implementation, Government of India. (n.d.-b). Annual survey of industries: Pharmaceutical units by state. Government of India.

[17] Mordor Intelligence. (2025). Indian pharmaceutical industry report 2031.

Pharmaceutical Technology. (2023). Indian pharmaceutical manufacturing: Andhra Pradesh.

Pharmexcil. (2024a). Export statistics. Pharmaceuticals Export Promotion Council of India.

[1, 18] Pharmexcil. (2024b). State-wise pharmaceutical export statistics FY 2023–24. Pharmaceuticals Export Promotion Council of India.

[14, 16] Press Information Bureau. (2023, August). Launch of PRIP scheme for promotion of research and innovation in pharma-MedTech [Press release]. https://www.pib.gov.in/PressReleasePage.aspx?PRID=1960812

[9] Scispot. (2026, February). Top biotech companies in Bangalore.

Telecom Talk. (2026). Indian pharmaceutical industry projected to reach USD 130 billion by 2030.

Times of India. (2024a). Gujarat pharmaceutical manufacturing and exports.

[6] Times of India. (2024b). Telangana bulk drug production.

[8] BCC Research. (2025). Top 10 companies leading the global biosimilars market.

[8, 18] Biocon Limited. (2025). Corporate website – Biocon Biologics among world’s top five biosimilar companies.

[12] BioSpectrum India. (2023, May 1). Thrust on innovation & R&D fundamental for Indian pharma’s growth. https://www.biospectrumindia.com/views/17/23031/thrust-on-innovation-rd-fundamental-for-indian-pharmas-growth.html

[14] BusinessToday. (2024, June 30). India’s pharma sector sees Rs. 29,268 crore investment under PLI scheme by May 2024. https://www.businesstoday.in/industry/pharma/story/indias-pharma-sector-sees-rs-29268-crore-increase-under-pli-scheme-by-may-2024-435225-2024-06-30

[13] CareEdge Ratings. (2025). USFDA inspections rebound: Indian pharma at the crossroads of opportunity and compliance. https://www.careratings.com/uploads/newsfiles/1750843740_Indian%20Pharma%20-%20CareEdge%20Report.pdf

[15] Department of Pharmaceuticals, Government of India. (n.d.-c). Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.

[2, 4, 7] India Brand Equity Foundation. (n.d.-c). Pharmaceutical industry in India. Ministry of Commerce and Industry.

[2, 3] Pharmaceuticals Export Promotion Council of India (Pharmexcil). (2025). Export statistics and pharmaceutical export data FY 2024–25.

[3] Press Information Bureau, Government of India. (2025, December 18). Indian pharma exports jump over 9% to USD 30.47 billion in 2024–25: Commerce Secretary. https://www.pib.gov.in/PressReleasePage.aspx?PRID=2205547

[19] Nordea & Changing Markets Foundation. (2018). Hyderabad’s pharmaceutical pollution crisis: Heavy metal and solvent contamination at factories in a major Indian drug manufacturing hub. Changing Markets Foundation.

[20] Department for Business and Trade, Government of the United Kingdom. (2025). India–UK Free Trade Agreement: Agreed in principle. HM Government.

[21] US Food & Drug Administration. (2017, March 28). FDA in India – Championing a culture of quality. FDA Voice. https://blogs.fda.gov/fdavoice/index.php/2017/03/fda-in-india-championing-a-culture-of-quality/

Disclaimer: Michelle Teresa Sebastian is a Research Intern at the Deccan Centre for International Relations and is currently an undergraduate student at Christ University, Bangalore. The views expressed in the article are those of the author and do not reflect the views of the Deccan Centre for International Relations.